Skip to main content
. 2009 Jul 15;66(18):3067–3080. doi: 10.1007/s00018-009-0090-7

Fig. 1.

Fig. 1

Specific binding of ICOSIg to ICOSL on DCs inhibits MLR. a–c DCs were treated as described in the text, and the histogram shows the fluorescence labeling-isotype antibodies. a ICOSIg binds specifically to DCs: thin line (red) 60 μg/ml ICOSIg + anti-IgG-PE; bold line (green) 60 μg/ml IgG + anti-IgG-PE. b ICOSIg binds competitively with anti-ICOSL to ICOSL on DCs: dashed line (red) only anti-ICOSL-PE; thin line (black) 30 μg/ml ICOSIg + anti-ICOSL-PE; bold line (green) 60 μg/ml ICOSIg + anti-ICOSL-PE. c Pretreated with ICOSIg completely blocks the specific binding of anti-ICOSL to ICOSL on DCs: thin line (red) 60 μg/ml IgG + anti-ICOSL-PE; bold line (green) 60 μg/ml ICOSIg + anti-ICOSL-PE. d More than 98% of the constructed ICOS transfectants express membrane-bound ICOS as determined by a specific anti-ICOS-PE antibody: histogram: CHO-CON + anti-ICOS-PE; bold line (green) CHO-ICOS + anti-ICOS-PE. e MLR were partially inhibited in the presence of ICOSIg compared to IgG1 (mean ± SD; *P < 0.05)